Core Viewpoint - The National Healthcare Security Administration has announced the 11th batch of centralized drug procurement, which will take place on October 21, covering 55 varieties and 162 specifications, including key areas such as antiviral and kidney disease treatment drugs [1][2]. Group 1: Drug Procurement Policy - The 11th batch of centralized procurement aims to stabilize clinical practices, ensure quality, prevent collusion, and avoid excessive competition [1]. - The new procurement rules will optimize price control mechanisms to prevent companies from underbidding, which previously led to unsustainable low prices [1][4]. - The focus on high-value consumables and medical devices is expected to benefit companies with strong cost advantages and product quality, particularly in major categories like cardiovascular and anti-infection drugs [4][5]. Group 2: Market Opportunities and Challenges - The centralized procurement policy presents both opportunities and challenges for pharmaceutical companies, prompting some generic drug firms to shift towards a combination of generics and innovation [2][5]. - The "anti-involution" trend in the procurement sector is expected to primarily benefit high-value consumables, which have been adversely affected by previous procurement rounds [2][4]. Group 3: Long-term Investment Perspective - Investors are advised to adopt a long-term perspective, as some innovative drug stocks are currently overvalued following previous market enthusiasm [3][9]. - The ongoing improvement of procurement policies is seen as a catalyst for the healthy development of the pharmaceutical industry, favoring large innovative drug companies with strong R&D capabilities [5][9]. Group 4: Company Performance and Projections - Companies like Kelun Pharmaceutical, Jingxin Pharmaceutical, and Fosun Pharma are highlighted for their strong R&D pipelines and potential for growth, with Kelun having over 30 projects focused on oncology [6][7]. - Fosun Pharma has made significant progress in its innovative transformation, with multiple products showing promising clinical trial results [6][8]. - China National Pharmaceutical Group is expected to have nearly 20 innovative products approved in the next three years, with several projected to exceed sales of 2 billion RMB [8].

Group 1 - The chemical pharmaceutical sector increased by 1.63% on September 30, with Mengke Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] - Notable gainers in the chemical pharmaceutical sector included Mengke Pharmaceutical, which rose by 8.45% to a closing price of 9.11, and Yong'an Pharmaceutical, which increased by 6.92% to 18.08 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 256 million yuan from main funds, while retail investors experienced a net outflow of 320 million yuan [2] - Key stocks with significant main fund inflows included Heng Rui Pharmaceutical with 37.4 million yuan and Yong'an Pharmaceutical with 134 million yuan [3] - Conversely, stocks like ST Suwu and ST Fuhua experienced declines of 5.00% and 4.97%, respectively, indicating a mixed performance within the sector [2]

Group 1 - The core point of the news is that Jingxin Pharmaceutical experienced a stock price increase of 5.39% on September 30, reaching 20.72 CNY per share, with a trading volume of 233 million CNY and a turnover rate of 1.59%, resulting in a total market capitalization of 17.841 billion CNY [1] - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, is located in Zhejiang Province and specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1] Group 2 - Red Soil Innovation Fund has a significant holding in Jingxin Pharmaceutical, with its fund "Red Soil Innovation Steady Mixed A" (006700) increasing its stake by 68,000 shares in the second quarter, bringing the total to 395,700 shares, which accounts for 2.95% of the fund's net value, making it the fifth-largest holding [2] - The fund "Red Soil Innovation Steady Mixed A" was established on March 13, 2019, with a latest scale of 74.8024 million CNY, achieving a year-to-date return of 1.64% and a one-year return of 2.86% [2] - The fund has a cumulative return of 59.19% since its inception [2]

Group 1 - The core point of the article is that Jingxin Pharmaceutical (002020.SZ) has announced its fourth employee stock ownership plan, aiming to raise a total of no more than RMB 150 million [1] - The employee stock ownership plan will allow employees to participate in the plan with a subscription unit of "shares," with each share priced at RMB 1, totaling up to 150 million shares [1] - The plan involves purchasing the company's repurchased shares at a price of RMB 12.50 per share, including reserved shares, with a total of 12 million shares involved, accounting for approximately 1.39% of the company's existing total share capital of 861.02914 million shares [1] Group 2 - The initial transfer portion of the plan consists of 10.52 million shares, which represents 87.67% of the total shares involved in this employee stock ownership plan [1]

证券简称：京新药业 证券代码：002020 浙江京新药业股份有限公司 第四期员工持股计划 （草案） 一、本员工持股计划须经公司股东大会批准后方可实施，后续能否获得公司 股东大会批准尚存在不确定性。 二、有关本员工持股计划的具体参与人数、资金来源、出资规模、实施方案 等属初步方案，本员工持股计划能否最终完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则参与本员工持股计划。若 员工认购金额较低时，本员工持股计划存在不成立或者低于预计规模的风险。 二零二五年九月 浙江京新药业股份有限公司第四期员工持股计划（草案） 声 明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2/42 浙江京新药业股份有限公司第四期员工持股计划（草案） 风险提示 五、本员工持股计划的资金来源为持有人个人的合法薪酬、自筹资金以及法 律、行政法规允许的其他方式。公司不以任何方式向持有人提供垫资、担保、借 贷等财务资助。本员工持股计划不涉及杠杆资金。 四、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3/42 浙江京新药业股份有限公司第四期员工 ...

证券代码：002020 证券简称：京新药业 公告编号：2025052 浙江京新药业股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 3、会议召开的合法、合规性：经公司第八届董事会第十八次会议审议同意 召开 2025 年第二次临时股东会，其召集程序符合《公司法》等有关法律法规、 部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： 现场会议时间：2025 年 10 月 20 日下午 14:00 起。 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 20 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的具体时间为 2025 年 10 月 20 日上午 9:15 至下午 3:00 的任意时间。 5、会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。公 司将通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络形式 的投票平台，公司股东可以在上述网络投票时间内通过深圳证券 ...

证券代码：002020 证券简称：京新药业 公告编号：2025051 浙江京新药业股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第八届监事会第十五次会议 通知于2025年9月23日以电子邮件形式发出，会议于2025年9月29日在公司行政楼一 楼会议室召开。会议应到监事3名，实到3名，会议召开符合《公司法》和《公司章 程》的有关规定。会议由监事会主席胡天庆先生主持，会议审核了如下决议： 1、审核《关于公司<第四期员工持股计划（草案）>及其摘要的议案》，本议案 需提交公司股东会审议。 关联监事回避后，监事会的非关联监事人数不足监事会人数半数以上，监事会 无法做出有效决议，本议案尚需提交公司2025年第二次临时股东会审议通过。详见 公司在《证券时报》、《中国证券报》和巨潮资讯网http://www.cninfo.com.cn刊登的 《浙江京新药业股份有限公司第四期员工持股计划管理办法》。 特此公告。 关联监事回避后，监事会的非关联监事人数不足监事会人数半数以上，监事会 无法 ...

证券代码：002020 证券简称：京新药业 公告编号：2025050 浙江京新药业股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第八届董事会第十八次会议通 知于2025年9月23日以电子邮件形式发出，会议于2025年9月29日以电话及传真方式 召开。会议应参加表决的董事9名，实际参加表决的董事9名。会议召开符合《公司 法》及《公司章程》的有关规定。会议经表决形成如下决议： 1、以6票同意、0票反对和0票弃权的表决结果，审议通过了《关于公司<第四期 员工持股计划（草案）>及其摘要的议案》； 为建立和完善员工、股东的利益共享机制，改善公司治理水平，提高员工的凝 聚力和公司竞争力，调动员工的积极性和创造性，促进公司长期、持续、健康发展， 在充分保障股东利益的前提下，按照收益与贡献对等的原则，公司根据《中华人民 共和国公司法》《中华人民共和国证券法》《关于上市公司实施员工持股计划试点 的指导意见》等有关法律、法规和规范性文件以及《公司章程》的规定，拟实施公 司第四期员工持股计 ...

Company Overview - Jingxin Pharmaceutical (SZ 002020) announced on September 29 that its 18th meeting of the 8th board of directors was held via telephone and fax, where the proposal for the fourth employee stock ownership plan was discussed [1] - As of the report date, Jingxin Pharmaceutical has a market capitalization of 16.9 billion yuan [1] Financial Performance - For the first half of 2025, Jingxin Pharmaceutical's revenue composition is as follows: finished drugs accounted for 58.28%, raw materials accounted for 22.44%, medical devices accounted for 17.32%, and other businesses accounted for 1.95% [1]

浙江京新药业股份有限公司 第四期员工持股计划管理办法 第一章 总则 第一条 为规范浙江京新药业股份有限公司（以下简称"京新药业"或"公 司"）第四期员工持股计划（以下简称"本员工持股计划"）的实施，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》（以下 简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》（以下简称"《自律监管指引第 1 号》"）等相关法律、行政 法规、规范性文件和《浙江京新药业股份有限公司章程》（以下简称"《公司章程》"） 之规定，特制定《浙江京新药业股份有限公司第四期员工持股计划管理办法》（以 下简称"本管理办法"）。 第二章 本员工持股计划的制定 《浙江京新药业股份有限公司第四期员工持股计划（草案）》（以下简称"本 员工持股计划草案"）根据《公司法》《证券法》《指导意见》《自律监管指引第 1 号》以及其他法律、行政法规、规范性文件和《公司章程》制定，遵循公平、 公正、公开的原则，旨在进一步健全和完善公司员工与公司股东的利益共享机制， ...